Podcasts about colloquia

Captīvus līberātus Richardus Grenell, lēgātus Americānus, nūntiāvit sē Iōsēphum St. Clair, cīvem Americānum quem Venetiolānī vinculīs ā mēnse Novembrī tenuerant, in Americam reduxisse. Mēnse Iānuāriō Grenell sex aliōs cīvēs redūxerat. Terror in Vasintōniā urbe Ēlīas Rodriguez, vir Sicagēnsis trigintā annōs nātus, reus est homicidiī. Fertur enim Vasintōniae (in urbe Columbiae prōvinciae) extrā mūsēum Iūdaicum duōs Isrāēlītās, quī in sēde lēgātiōnis muneribus fungī solēbant, occīdisse; quī et, dum comprehendēbātur, identidem clamābat ut Palaestīna līberārētur. Foederālis Sedes Investīgandō nuntiāvit sē certiōrem factam esse Rodriguez nōnnulla scrīpsisse, quae vidērentur terrōrem in Isrāēlītās prōmōvēre; necnōn participem fuisse gregum quī extrēmīs partibus sinistrīs favērent. Colloquia inter Russōs et Ūcrāīnēnsēs Colloquia prīma, quae post trēs annōs inter magistrātūs Russōrum et Ūcrāīnēnsium habita sunt, post duās hōrās nōn sine fructū sunt ad fīnem perducta. Cōnsēnsī enim sunt lēgātī mille utrīusque gentis captīvārum līberāre, quae mūtua remissiō erit hūius bellī maxima. Russī autem magistrātūs dīxērunt colloquia sibi placuisse, sē porro velle pergere cum Ūcrāīnēnsibus dē pāce conciliandā colloquī. Coniūrātī in Ceirum Starmer In Britanniā duo hominēs, Rōmānus Lavynovych Ūcrāīnēnsis et Stanislaus Capiuc Romāniānus in occidentālī Ūcrāīnā nātus, reī sunt cōniūrātiōnis adversum Ceirum Starmer: nam tria incendia fēcērunt in locīs, ubi Ceirus Starmer, minister prīmārius Britannōrum, ōlim habitāverat. Incertum est, ob quam causam illī incendia fēcerint. Eurovīsiō Basilēae in Cōnfoederātiōne Helveticā, Iōhannēs Pietsch, cantor Austriacus, victōriam tulit certāminis totīus Eurōpae, quod Eurovīsiō dīcitur. Pietsch, contrātenor altus quī “Amōrem Perditum” cecinit, spērat sē cum Conchīta Wurst, quae annō bis millēsimō quartō decimō palmam rettulit, praefūtūrum proximō certāminī, quod in Austriā habēbitur. Dan victor Comitiīs in Rōmāniā diē Sōlis habitīs, Nicūsor Dan victor ēvāsit. Geōrgius Simiōn, quī priōribus in comitiīs vidēbātur plūrimum pollēre, Nicūsōrī concessit, postquam falsō nūntiāverat sē victōrem esse. Magistrātūs autem Gallōrum negant id, quod Pavelus Durov, praefectus societātī Tēlegrammatī dictae, cūius ope hominēs clam atque ēlectronicē colloquuntur, accūsāvit, vidēlicet ā suīs speculātōribus postulātum esse, ut Tēlegramma arcēret hominēs dextrārum partium, quōminus dē rē politicā Rōmāniānōrum colloquerentur. Sed, cum rumor illīus postulātiōnis ortus esset, Simiōn dīxit sē rogātūrum esse ut iūdicēs, quī priōra comitia abrogāvissent propter rumōrem, quō Russī per TikTok comitia clam aggressī esse putābantur, etiam novissima comitia abrogārent propter similem rumōrem, quō Gallī per Tēlegramma comitia clam aggressī esse putābantur. Nāvis Cōrēāna statim dēmersa Diē Mercuriī, Chongjin in Cōrēā Boreālī, novissima nāvis bellica, quae in mare dēdūcēbātur, subitō coram multīs necnōn etiam Kim Jong-un ipsō ēversa naufrāgium fēcit. Kim ipse in nāvālia excanduit: nōn modo calamitātem esse sed crīmen negligentiæ, quæ dignitātem totīus gentis maculāret nec tolerātum īrī. Iussit porro nāvem, quae nunc mersa iacet, ante mēnsem Iūlium ē marī tollī reficīque. Ἡ ὀρύζα ἐν Ἰαπωνίᾳ ἀνατιμᾶται ἡ τῶν Ἰαπώνων πολιτῶν εὔνοια πρὸς τὸν Σιγηρέα Ἰσίβαν, τὸν τὴν μεγίστην ἐν Ἰαπωνίᾳ ἀρχὴν ἔχοντα, εἰς τὸ ἐλάχιστον κατήχθη, ὥστε ἔννεα μέρη τῶν πολιτῶν πρὸς Ἰσίβαν ἀγανακτοῦσι διὰ τὴν τῆς ὀρύζης ἐπιτίμησιν. ἡ γὰρ ὀρύζης τιμὴ σχεδὸν διπλασία ἐν τῷ αὐτῷ ἔτει γέγονεν. ὁ δὲ Τακεὺς Ἠτών, ὁ έπὶ τῇ γεωργίᾳ ἄρχων, μεγαλαυχήσας οὐδέποτε χρῆναι ἑαυτὸν, ὡς πολλὰ δῶρα δεχόμενον, ὀρύζαν πρίασθαι, τῇ μὲν Σελήνης ἡμέρᾳ συνέγνω τὸ τῆς ἀλογίας καὶ ὕβρεως ἁμάρτημα· τῇ δὲ Ἑρμοῦ ἠναγκάσθη τῆς ἀρχῆς ἀφίστασθαι. Κουαουτέμοκ τῇ Βροῦκλιν γεφύρᾳ συνέκρουσεν ἡμέρᾳ Κρόνου ἐν τῷ Νέῳ Ἐβοράκῳ μακρὰ ναῦς τοῦ Μεξικανικοῦ στόλου, Κουαουτέμοκ κεκλημένη, ἐκ τοῦ λιμένος ἀναχωρήσασα, ἐλαυνομένης δυνάμεως ἐκλιπούσης, πολλῷ ῥεύματι παλιμπρυμνηδὸν φερομένη, τῇ γεφύρᾳ τῇ Βροῦκλιν καλουμένῃ συνέκρουσεν. τῶν ναυτῶν, ὧν πολλοὶ ἐπὶ τῶν κεραιῶν ἵσταντο, ἀπέθανον μὲν δύο, ἐκομίσθησαν δὲ τραυματίαι δύο καὶ εἴκοσιν. τῆς μὲν νεὼς πάντες οἱ ἱστοὶ κατερράγησαν, ἡ δὲ Βροῦκλιν γεφύρα διὰ τὴν ἰσχὺν ἀβλαβὴς διαμένει. οἱ οὖν ἄρχοντες τοῦ Νέου Ἐβοράκου ζήτουσιν αἰτίαν τῆς συμφορᾶς. Brennus Legrānus diem obiit Brennus Legrānus, quī et Brian Reynold Bishop Anglicē nōminātus est, Britannus et strenuus fautor Latīnitātis vīvae, diem obiit. Quī nōn sōlum Latīnae linguae prōmovendae operam dedit sed etiam Volapüka linguae ūniversālis annō millēsimō nōningentēsimō octōgēsimō quartō creātus est septimus praeses, quī cifal eō sermōne vocātur. Vīxit annōs nōnāgintā et ūnum. Laudēs in Byrōnem Stayskal dicendae Byrōn Stayskal, professor ūtrīusque sermōnis quī saepissimē linguam Graecam nostrā in studiōrum Ūniversitāte docet, hōc annō acadēmicō peractō rude donābitur et in Colōrātam cīvitātem lārēs trānsferet. Septindecim enim annōs docuit apud Occidentālem studiōrum Ūniversitātem Vasintōniēnsem. Cūius gravis et melliflua vox nōnnullīs nōta est, quī Nūntiōs Latīnōs Vasintōniēnsēs auscultant. In quem laudēs dicentur quartā hōrā, secundō diē mēnsis Iūniī, in centēsimō vīcēsimō prīmō conclāvī aedium Milleriānārum.

IN HOC PROGRAMMA’ ‘DE WHEELOCK 6th , Ed. capite tertio, paginis 17-23: de nominibus et adiectivis omnibus casibus ex secunda declinatione, de appositione, et de verborum ordine in oratione vel sententia’ ‘SEQUIMUR’ [QUIA “NUNTII IN LINGUA LATINA” ‘INSTRUMENTUM’ ‘AD LATINUM DISCENDUM ET DOCENDUMQUE’ ‘EST’]. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET GALLICA’ ‘*AUDIS’! CIVITATES FOEDERATAE AMERICAE ET RUSSIA CONTRA EUROPAM ET UCRAINAM. 14 TRANSLATIO A FERNANDA SOLÍS VERSAM EST. ‘*CIVITATES FOEDERATAE AMERICAE ET *RUSSIA ‘COLLOQUIA’ ‘DE UCRANIA’ , ‘SINE KIOVIA NEQUE UNIONE EUROPAEA ‘*INEUNT’ . // ‘*EUROPA PERTURBATA ‘*EST’ ‘QUIA DEFENSIONEM SUAM SINE AMERICA ‘COGITARE’ ‘INDIGET’ . AEGYPTO. TRANSLATIO AB ALISSA SOUZA VERSAM EST. ‘*CAIRUS’ ‘SUUM CONSILIUM’ ‘PRO GAZA’ ‘*PARAT’. // ‘*NATIONES ARABICAE’ ‘SUAS OPTIONES’ ‘IMPROVISO IMPETU’ ‘A DONALDO TRUMP, CIVITATUM FOEDERATAE AMERICAE PRAESIDE,’ ‘CAPTAE’ ‘*PRAEPARANT’. //. ‘*AEGYPTUS’ ‘CONSILIUM’ ‘DE REFICIENDO HOC TERRITORIO PALAESTINENSI’ ‘CUM ARGENTARIA MUNDANA’ ‘*EXCOLIT’. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis, quae sunt? ¿1 vel plures appositionem invenis? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET ITALICA’ ‘*AUDIS’! CIVITAITS VATICANAE STATU. ‘PAPA *FRANCISCUS’ ‘IN VALETUDINARIO’ ‘AD ANALYSES FACENDUM’ ‘*EST’ . // ‘*FRANCISCUS, PAPA ECCLESIAE CATHOLICAE ROMANAE 15 A TERTIO DECIMO DIE MARTIIS MENSE ANNO DOMINI BIS MILLÉSIMO DECIMO TERTIO,’ ‘IN VALETUDINARIO’ ‘*MANET’ [QUIA ‘ANALYSES’ ‘MORBOS MULTIPLICES’ ‘*OSTENDUNT’]. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis, quae sunt? ¿1 vel plures appositionem invenis? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET GERMANICA ‘*AUDIS’! TRANSLATIO AB ALISSA SOUZA VERSAM EST. UCRAINA. BELLATOR SOLITARIUS. // [CUM ‘*RUSSIA’ ‘URAINAM’ ‘*INVADEBAT’], ‘*VLADIMIRUS ZELENS’KYJ, UCRAINAE PRAESES’ ‘BELLUM DOMINATOR’ ET , ‘QUOMODO WINSTON CHURCHILL’ ‘PUTATUS EST’. // ‘ID EST: FORTIS ET FIRMUS’ . // ‘NUNC VERO’ ‘DONALDUS , TRUMP, DENUO CIVITATUM FOEDERATAE AMERICAE PRAESES’ , ‘EUM’ ‘RELIQUIT’. // ‘*ZELENS’KYJ’ ‘IPSE SIT’ ‘IAM *NESCIT’ . {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis, quae sunt? ¿1 vel 2 appositiones invenis, quae sunt? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. 16 IN ORBE TERRARUM. ‘*AGE’, ‘ORBEM TERRARUM’ ‘*DIVIDAMUS’. // ‘FOEDUS’ INTER ‘TRUMP, ITERUM C-F-A PRAESES A DIE VICESIMO MENSE IANUARII HOC ANNO’ , ET ‘PUTIN, ITERUM FOEDERATIONIS RUSSICAE PRAESES A ANNO BIS MILLESIMO DUOCESIMO’ , UCRAINAM AESTUAT ET SOCIA CONCUTIT. // ¿‘INTER EOSNE’ ‘EUROPAE PACEM ET FUTURUM’ ‘*DECIDENT’? {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Nomina et adiectiva in secunda declinatione invenis? ¿2 appositiones invenis, quae sunt? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET HISPANICA’ ‘*AUDIS’! MEXICO. MEXICOPOLIS. ‘AEROPLANA NON GUBERNATA SPECULATORIAS. // ‘TRUMP *REGIMEN’ ‘SEDIS CENTRALIS EXPLORATORIAE’ ‘AEROPLANA NON GUBERNATA SPECULATORIAS, ID EST , VEL VEHICULUM AERIUM EXPLORANS SINE GUBERNATOR, ’ ‘AD NARCOTICORUM CULINAS IN MEXICO INVENIENDUM’ ‘*UTUNTUR’. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis? ¿1 appositiones invenis, quae 17 sunt? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET RUSSICA’ ‘AUDIS’! TRANSLATIONES A SAID RAYMUNDO DELGADO VERSA SUNT. TRUMP ADVERSUS ZELENSKY. '*TRUMP' 'APROBATIONEM ZELENSKII' 'AD QUATTUOR PARTES EX CENTUM CECIDIT' '*DIXIT'. // 'ESTNE HOC VERUM?' // '*ORATIO DONALD TRUMP' 'ERGA UCRANIAM ET ERGA VOLODYMYR ZELESNKY, UCRAINAE PRAESES,' MAGIS HOSTILIS' '*FIT'. // '*TRUMP, DUX CIVITATIUM FOEDERATAE AMERICAE,' 'DIE DUODEVIGINTI FEBRUARII MENSE' '*ITERAVIT': 'SECUNDUM SUA SENTENTIAM', '*ELECTIONES PRAESIDENCIALES' 'IN UCRANIA IN MOMENTO FUTURO PROXIMO' '*HABENDAE ESSE'. // 'SECUNDUM TRUMP': ('HOC DICERE' '*NON PLACET') '*VALOR APROBATIONIS ZELENSKY' QUTUOR PARTES EX CENTUM TANTUM' '*EST'. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿1 vel plures appositionem invenis? ¿Verborum ordo in orationes vel sententias adaequatus est?}. DENUO TRUMP ADVERSUS ZELENSKY. -"*EGO' 'STATUM' 'VENDERE NON *POSSUM."- // '*ZELENSKY' ['CUR PROPOSITIONEM CIVITATIUM 18 FOEDERATAE AMERICAE' 'DE OPIBUS MINERALIBUS' '*REIECIT']' *EXPLICAVIT'. // ET '*ZELENSKY' 'AD TRUMP', ['*QUI' 'ELECTIONES' 'IN UCRANIA' ' *PETIVIT']' *RESPONDIT'. // -"SI '*ALIQUIS' 'ME MUTARE' 'HOC TEMPORE' '*VULT', TUNC: ['*HOC' '*NON EFFICIET']. // PRAETEREA '*CORRUPTIO INFORMATIONIS' 'DE CASU VALORIS APROBATIONIS' 'A RUSIA' '*PROVENIT'.- // '*ADMINISTRATIO TRUMP' 'SUAM ATTITUDINEM ERGA RUSSIAM' '*LENIVIT'. // 'BELLUM '*NON APELLAT', SED 'CONTENTIONEM'. ‘NUNTII IN LINGUA LATINA’ ‘IN LINGUA LATINA, ANGLICA ET SINENSIS PINYIN’ ‘*AUDIS’! TRANSLATIONES A CASANDRA FREIRE VERSA SUNT. SINIS. ‘DIE QUATTUORDECIM FEBRUARII’ ‘*COLLOQUIUM’ ‘SUCHEI ANNI BIS MILLESIMO VICESIMO QUINTO’ ‘PROMOTIONIS PROGRESSIONIS ET INNOVATIONIS INTELLIGENTIAE ARTIFICIALIS’ ET ‘*COLLOQUIUM’ ‘POTESTATIS NOVAE INDUSTRIALIZATIONIS ARTIFICIALIS INTELLIGENTIAE’ ‘*EVENERANT’ . // ‘IN THEMATE’ ‘*TRACTANDO’ "*INTELLEGENTIA ARTIFICIALIS’ ET ‘BONA *QUALITAS’ ‘NOVUM FUTURUM’ ‘*DUCIT", ‘PLUS QUAM CENTUM’ ‘*EXEMPLA’ ‘[UT ROBOTA HUMANOIDES, [ID EST ROBOTUM CORPUS SIMILIS HOMINI], RATIONES MODERATORUM 19 INTELLIGENTIUM] ET ‘* EXEMPLARIA VIRTUALIUM INTERACTIVORUM’ [CUM MAGNA-SCALAE INTERACTIVA AI, [ ID EST INTELLEGENTIA ARTIFICIALIS]] ‘*REVELATI SUNT’ . {De Wheelock 6th Ed. Capite 2, ¿Nomen ex prima declinatione invenis quod quadruplex apparet?}. SINIS. ‘NOVAE INCLINATIONES, NOVA LOCA, NOVAE POTENTIAE’: ‘NOVI *MERCATUS’ ‘NOVUM VIGOREM OECONOMIAE SINENSIS ‘*DEMONSTRANT’ . // ‘PRIMO VER ‘*FESTO’ , [HOC DECLARANTE MUNDI HEREDITATIS] ‘*IUCUNDIUS EST’ ET ‘*MERCATUS NOVI ANNI’ ‘IN FLUMINE MERIDIANO’ ‘*VIVIDISSIMUM EST’. {De Wheelock 6th Ed. Capite 3, Paginis 17-23. In hoc nuntio inveni: ¿Quot nomina et adiectiva in secunda declinatione invenis, quae sunt? ¿Aliqua appositio invenis, quae est? ¿Verborum ordo in orationes vel sententias adaequatus est? ¿Lexico ex capite 3 invenis?}. LEXICON LEXICON EX “CIVITATES FOEDERATAE AMERICAE ET RUSSIA CONTRA EUROPAM ET UCRAINAM”… Nomina • America – America • Colloquia – Talks, negotiations • Civitates – States • Defensionem – Defense • Europa – Europe 20 • Foederatae – Allied (as a substantive: Allied States) • Kiovia – Kyiv • Russia – Russia • Unione – Union • Ucrania – Ukraine Adiectiva • Perturbata – Disturbed, troubled Verba • Cogito – I think, consider • Indigeo – I need, lack • Ineo – I enter, begin • Sum – I am LEXICON EX “AEGYPTO”… Nomina • Aegyptus – Egypt • Argentaria – Bank • Cairus – Cairo • Civitatum (genitivo plural de Civitas) – States • Consilium – Plan, decision • Foederatae – Allied (as a substantive: Allied States) • Gaza – Gaza • Impetu (ablativo de Impetus) – Attack, momentum • Mundana – World (as an adjective meaning "global") • Nationes – Nations • Optiones – Options, choices • Palaestinensi – Palestinian (adjective) • Praeses – President • Territorium – Territory Adiectiva 21 • Arabicae – Arabic • Captae – Captured, seized • Suas – Their own • Suum – Their own Verba • Excolo – I develop, cultivate • Paro – I prepare • Praeparo – I make ready, prepare LEXICON EX “CIVITAITS VATICANAE STATU”… Nomina • Analyses – Examinations, tests • Ecclesia – Church • Franciscus – Francis • Menses – Month • Morbos (acusativo plural de Morbus) – Diseases • Papa – Pope • Valetudinarium – Hospital Adiectiva • Catholica – Catholic • Multiplices – Multiple • Romana – Roman • Tertius – Third Verba • Maneo – I remain, stay • Ostendo – I show, reveal • Sum – I am LEXICON EX “UCRAINA”… Nomina • Bellator – Warrior • Bellum – War • Civitates – States 22 • Dominator – Ruler, master • Praeses – President • Russia – Russia • Ucraina – Ukraine • Zelens’kyj – Zelensky Adiectiva • Firmus – Strong, firm • Fortis – Brave, courageous • Solitarus – Lonely, solitary Verba • Nescio – I do not know • Sum – I am LEXICON EX “IN ORBE TERRARUM”… Nomina • Foederatio – Federation • Foedus – Treaty, alliance • Futurum – Future • Orbis – World, globe • Pax – Peace • Praeses – President • Russia – Russia • Socia – Ally • Ucraina – Ukraine Adiectiva • Russica – Russian Verba • Aestuo – I am in turmoil, I am agitated • Decido – I decide • Divido – I divide • Concutio – I shake, I disturb LEXICON EX “MEXICO”… Nomina • Aeroplanum – Airplane 23 • Culina – Kitchen (in this context: drug lab) • Mexico – Mexico • Regimen – Government • Sedes – Headquarters, seat • Vehiculum – Vehicle Adiectiva • Centralis – Central • Exploratorius – Exploratory, reconnaissance • Speculatorius – Surveillance, spy Verba • Invenio – I find, discover • Utor – I use (takes the ablative) LEXICON EX “TRUMP ADVERSUS ZELENSKY.”… Nomina • Aprobatio – Approval • Civitates – States • Dux – Leader • Electiones – Elections • Mensis – Month • Oratio – Speech, discourse • Praeses – President • Sententia – Opinion, judgment • Ucraina – Ukraine • Valor – Value Adiectiva • Foederatus – Allied • Futurus – Future • Hostilis – Hostile • Presidentialis – Presidential • Proximus – Near, close Verba • Dico – I say, speak • Fio – I become, happen 24 • Habeo – I have • Itero – I repeat • Placeo – I please, am agreeable • Sum – I am LEXICON EX “DENUO TRUMP ADVERSUS ZELENSKY.” Nomina • Administratio – Administration • Aprobatio – Approval • Bellum – War • Civitas – State • Contencio – Conflict, dispute • Corruptio – Corruption • Electio – Election • Informacio – Information • Minerale – Mineral • Opes – Resources, wealth • Russia – Russia • Status – State, condition • Valor – Value Adiectiva • Foederatus – Allied • Hoc – This • Suus – His, their own Verba • ApeIlo – I call, name • Efficio – I accomplish, achieve • Explico – I explain • Lenio – I soften, alleviate • Possum – I am able, I can • Provenio – I come forth, arise • Reicio – I reject • Respondeo – I reply, answer • Vendo – I sell 25 • Volo – I want, wish LEXICON EX “SINIS” … Nomina • Colloquium – Conference, discussion • Dies – Day • Exemplum – Example • Futurum – Future • Innovatio – Innovation • Intelligentia – Intelligence • Potestas – Power • Progressio – Progress • Promotio – Promotion • Qualitas – Quality • Ratio – System, method • Robotum – Robot • Themata – Theme, subject Adiectiva • Artificialis – Artificial • Humaniformis – Humanoid • Industrialis – Industrial • Interactivus – Interactive • Novus – New Verba • Duceo – I lead • Revelo – I reveal • Tracto – I handle, discuss LEXICON EX “SINIS” … Nomina • Economia – Economy • Flumen – River, stream • Hereditas – Heritage, inheritance • Mercatus – Market 26 • Mundi – World (genitive singular of Mundus) • Potentia – Power, potential • Vigor – Strength, vigor • Ver – Spring (season) Adiectiva • Novus – New • Sinensis – Chinese • Iucundus – Pleasant, enjoyable • Vividissimus – Very vivid, most vivid Verba • Demonstrato – I demonstrate • Vivo – I live SI NUNTII IN LINGUA LATINA TRADUCTOR ESSE VOLUERIS, QUAESO LITTERAM ELECTRONICAM AD lpesquera@up.edu.mx MITTAS’. If you would like to collaborate as a translator in Nuntii in Lingua Latina, please send an email to lpesquera@up.edu.mx

The bathhouse is an iconic feature of the medieval middle eastern city up until the present. But how did this come to be? In this episode we look into the origins of bathing culture in the Middle East by going back to the Roman, late antique and early Islamic development of bathhouses. Speakers: Nathalie de Haan and Sadi Maréchal. Interviewer: Edmund Hayes. Nathalie de Haan is an associate professor in ancient history at Radboud University, Department of History, Art History and Classics and RICH (Radboud Institute for Culture &History). She is the coordinator of the RICH research group The Ancient World. Her research interest include baths and bathing in the Roman world, Pompeii and Herculaneum and the history of classical archaeology in modern Italy (19th and 20th centuries). Sadi Maréchal is senior postdoctoral researcher of the Research Foundation Flanders (FWO) based at the department of Archaeology at Ghent University, part of the Historical Archaeology Research Group, the Mediterranean Archaeology Research Unit and coordinator of the Ghent Centre for Late Antiquity. This episode was produced by Edmund Hayes and Jouke Heringa. Further Reading Nathalie de Haan & Kurt Wallat, Die Zentralthermen (Terme Centrali) in Pompeji: Archäologie eines Bauprojektes, Papers of the Royal Netherlands Institute in Rome, 71 (Rome: Quasar, 2023). (see: https://edizioniquasar.it/products/die-zentralthermen-terme-centrali-in-pompeji-archaologie-eines-bauprojektes) Nathalie de Haan “Si aquae copia patiatur. Pompeian Private Baths and the Use of Water”, Chapter 4, in A.O. Koloski-Ostrow (ed.), Water Use and Hydraulics in the Roman City, Dubuque, Iowa: Kendall/Hunt Publishing Company (Archaeological Institute of America, Colloquia and Conference Papers, Vol. 3, 2001) Sadi Maréchal, Public Baths and Bathing Habits in Late Antiquity. A Study of the Evidence from Italy, North Africa and Palestine A.D. 285–700 (Late Antique Archaeology Supplementary Series 6), Leiden: Brill 2020. Sadi Maréchal, Washing the Body, Cleaning the Soul : Baths and Bathing Habits in a Christianising Society, Antiquité Tardive 28 (2020): 167–176. F. Yegül, Bathing in the Roman World (Cambridge: Cambridge University Press, 2010). Edmund Hayes twitter.com/Hedhayes20 https://www.linkedin.com/in/edmund-hayes-490913211/ https://leidenuniv.academia.edu/EdmundHayes https://hcommons.org/members/ephayes/ Abbasid History Podcast is sponspored by IHRC Bookshop Listeners get a 15% discount on all purchases online and in-store.  Visit IHRC bookshop at shop.ihrc.org and use discount code AHP15 at checkout.  Terms and conditions apply. Contact IHRC bookshop for details. https://linktr.ee/abbasidhistorypodcast  

1-III-2024. DE BELLO ISRAËLIANO-HAMASIANO ANNI DOMINI BIS MILESIMO VICESIMO TERTIO E VICESIMO QUARTO. ‘PALESTINENSES’ ‘Israelitis’ ‘ADESURIUNT’. /// ‘MAHMOUD ABBAS, praeses Civitatis Palestinae (sive Auctoritas Nationalis Palestina),’ ‘ABDICAT’. Pro informatione: AUCTORITAS NATIONALIS PALESTINA est rectio Palestinae ab anno Domini milesimo nongentesimo nonagesimo quarto ex Consociatione pro Liberatione Palestinae ab Iasser Arafat cum consensu Osloensi decreta (EX VICIPAEDIA). /// ‘In Gaza’, ‘triginta milia mortui’ ‘iam SUNT’. Pro informatione: Gaza est urbs et regio Palestinae circiter quadrigentorum milibus incolarum et caput Iaciniae Gazeticae (EX VICIPAEDIA). /// [‘COPIAE ad Israelem Defendendum (anglice I-De-eF)’ ‘DICIT’] [EOS tredecim milia Hamae tomocrates OCCIDISSE et EOS quattuor milia ASSULTUS FECISSE] {De syntaxe: infinitivi orationem secundariam completivam ATTENDE} /// [‘Plus quam centum palestinenses’ ‘mortui FUERUNT’], [quia ‘alimonia’ ‘in autocineta oneraria’ ‘QUAEREBANT’] {De syntaxe: causalem orationem secundariam in modo indicativo cum coniuctione ‘quia’ ATTENDE} IN ORBE TERRARUM. ‘Plus quam obesorum miliardum’ ‘in orbe terrarum’ ‘SUNT’. Vel SUMUS? /// ‘Antonius GUTERRES, secretarius generalis nationum Unitarum ab anno Domini bis millesimo septimo decimo,’ ‘de climatis discrimine’ ‘ADMONET’. IN CIVITATIBUS FOEDERATAE AMERICAE. TRANSLATIONES ab Israel García Avilés SUNT. /// Biden Michigan acquirit inter de rationi civile intercessionem Gazae. /// Administratio fructuum publicorum conqueritur propter immigrationem. /// McConell Senatum dicit momentum esse quod ipse debet regredi. /// McConell deponit tamquam dux Senati Congregationis Popularis Reipublicae. Senator octogenarius post duos decadas munerem deponit. /// Supremum Forum audire concordat petitiones immunitatis dictas a Trump. /// ‘Iosephus BIDEN praeses Civitatum Foederatarum, et TRUMP qui candidatum replubicanum nominaturus est,’ ‘ad finem cum Mexico’ ‘FUERUNT’. Ibi ‘sermones politicos’ ‘DEDERUNT’ {De syntaxe: orationem perifrasticam activam ATTENDE} IN BRITANNIÁRUM REGNO. ‘BRITANNIARUM REGNUM’ ‘Emmanuelis Macron consilium’ ‘ad copias in Ucrainam mittendum’ ‘OBSTRUIT’. /// ‘FAMILIA REGALIS anglica’ ‘mariti Gabriellae mors’ ‘COMMOVENTUR’. /// ‘DAVID CAMERON, minister rerum externarum Regni Britanniarum,’ ‘Vladimirum Putin, praeses Foederationis Russicae,’ ‘de Navalnyj Vidua’ ‘PREMIT’. IN CANÁDA. ‘Brianus MULRONEY, anterior Canadae primus minister,’ ‘PERIIT’. Requiescat in pace. IN FRANCIA. ‘Nongentae MACHINAE TRACTORIAE’ ‘in Bruxellis’ ‘contra ‘Pe-A-Ce’ ’ ‘PROTESTANTUR’. /// ‘EMMANUEL MACRON’ ‘de copiis in Ucrainam mittendo’ ‘solus MANET’. IN GERMANIA. ‘Olaus SCHOLZ, Germaniae cancellarius foederalis,’ ‘de copiis in Ucrainam mittendo’ ‘ABICIT’ {De morphologia: constructionem cum gerundio ATTENDE} /// ‘Olaus SCHOLZ et Emmanuel MACRON’ ‘in discordia’ ‘esse SOLENT’. /// ‘Vincula sempiterna’ ‘contra Ridouan Taghi’ ‘ERIT’. Pro informatione: ‘TAGHI, ‘dux maximus’ ‘inter medicamentorum stupefactivorum mercatores’ ‘EST’. /// ‘Anterior sodalis’ ‘ex Factione Excercitu Rubro (abbreviatione ‘eR-A-eF’) ’ ‘CAPTA FUIT’. /// ‘VENATIO’ ‘contra terroristas’ ‘CONTINUAT’ {Ex lexico: vox ‘terrorista’ etiam ‘tromocrata’ vel ‘territor’ ‘VOCATUR’} /// ‘INFLATIO monetalis’ ‘in Germania’ ‘ad duos punctum quinque centesimas’ ‘CADIT’. IN RUSSIA. [‘PUTIN’ ‘AMONET’] quod [si Europa copias ad Ucrainam MITTAT], [‘bellum nucleare’ ‘PROVOCET’] {De syntaxe: orationem secundariam relativam et orationem secundariam hypotheticam ATTENDE} /// ‘Tametsi interdictum’, ‘milia et milia’ ‘ad Navalyj funus’ ‘in Moscovia’ ‘FUERUNT’ {De syntaxe: orationem secundariam consessivam in modo indicativo cum coniuctione ‘tametsi’ ATTENDE} Pro informatione: ‘Alexius Anatolii filius NAVALNYJ’ ‘oppositions dux et caput politus’ ‘contra Putin’ ‘FUIT’. ‘Anterior hebdomada’ ‘in carcere’ ‘mortuus FUIT’. /// [‘MOSCOVIA’ ‘tributa’ ‘REDUCET’], [ut ‘suffragia’ ‘pro comitiis proximis’ ‘LUCRETUR’] {De syntaxe: orationem secundariam consecutivam in modo subiunctivo cum coniuctione ‘ut’ ATTENDE} IN LUSITANIA. ‘SEX PUNTCII’ ‘A-De a Pe-eS’ ‘SEPARANT’. IN ISRAELE. ‘In Israelis comitiis localibus’, ‘ultra orthodoxos’ ‘suffrratia’ ‘LUCRANT’. IN INDIA. ‘PRIMUS MINISTER’ ‘quattuor astronautas’ ‘pro Gaganyaan missione’ ‘NOMINAT’ {Ex lexico: vox ‘astronauta’ etiam ‘cosmonauta’ vel ‘nauta sideralis’ DICITUR} IN SINAE. ‘Qin Gang, anterior Sinarum rerum externarum MINISTER,’ ‘ex Factione Communista’ ‘ABDICAT’. IN COREA SEPTRENTIONALE. ‘GIM JEONG-EUN, princeps coreae Septentrionalis ex anno Domini bis milesimo undicesimo’, ‘armamentarium nucleare’, ‘dum orbe terrarum altera parte videt’, ‘AUGET’ {De syntaxe: orationem secundariam temporalem in modo indicativo cum coniuctione ‘dum’ ATTENDE} IN BRASILIA. ‘Vigilium OPERATIO’ in ‘favelas’ ‘novem mortuos et duos vulneratos’ ‘RELIQUIT’. /// ‘Aloysius Ignatius Lula da Silva, praeses Brasiliae,’ ‘consilium tributarium novum’ ‘ad Congressum’ ‘MITTET’. /// ‘G-Viginti’ ‘de tributiis, de inaequalitate et de oecologia’ ‘COLLOQUUNTUR’. /// ‘Frebis dengue EPIDEMIA’ AUGMENTAT. Pro informatione: Febris dengue est morbus tropicus ab viro dengue effectus, a culicibus vectus (EX VICIPAEDIA). IN CIVITATES FOEDERATAE AMERICAE. ‘Iosephus Robinette BIDEN, praeses Civitatum Foederatarum, et Donaldus Ioannes TRUMP, anterior praeses Civitatum Foederatarum,’ ‘in Michigania’ ‘VINCUNT’. IN EUROPA. ‘URSULA DE LEYEN (vulgo von der Leyen), praesidem Commissionis Europaeae’, ‘armare’ ‘Europae’ ‘PETIT’. /// ‘URSULA DE LEYEN’ ‘candidatum’ ‘ad alterum mandatum’ ‘ad Commissionem Europaeam praesidendum’ ‘ERIT’. IN UCRÁINA. ‘Europae COPIAE’ ‘ad Ucrainam’ ‘non MISSI ERUNT’. /// ‘In Gaza’, ‘Israelis milites’ ‘in picturam motinis’ ‘abusus suos’ ‘CAPIUNT’. IN ITALIA. ‘TODDE’ ‘VINCIT’ et ‘TRUZZU’ ‘PERDIT’. /// ‘FOEDUS’ ‘in discrimen’ ‘EST’. IN FRANCIA. ‘TRISTITIA et PAENITENTIA’ ‘ex Franciae episcopis’ ‘abortus inclusione’ ‘in Lege Primaria Rei Publicae’. IN HELVETIA. ‘Administrationis publicae OPERISTITIUM magnum’ ‘in Ticino’ ‘FUIT’. ‘Circa quinque milia personae’ ‘contra regiminis oeconomicas contractiones’ ‘RECLAMANT’. IN QUATARIA. ‘In Doha, ‘urbs et caput Quatariae’, ‘COLLOQUIA’ ‘pro armistitio’ ‘in Gaza’ ‘SUNT’. IN TZADIA. ‘TZADIA’ ‘civitas’ ‘in chaos’ ‘EST’. IN ZAMBIA. ‘Zambia’ ‘In status extraordinario’ ‘siccitate’ ‘EST’. IN EUROPA. ‘URSULA DE LEYEN’ ‘exemplar contra coronae virus’ ‘nunc pro armas emendum’ ‘uti VULT’. IN HISPANIA. [‘ÁBALOS’ ‘DICIT’] [‘ME’ ‘non abdicturum esse’] {De syntaxe: orationem secundariam completivam in infinitivo ATTENDE} /// ‘Rex et anterior rex’ ‘inter eos’ ‘PROGREDIUNTUR’. /// ‘Supremum TRIBUNAL’ ‘casum’ ‘contra Puigdemont’ ‘in Tsunami’ ‘terrorismo’ ‘CONSIDERAT’. IN MEXICO. TRANSLATIONES a Casandra Freire SUNT. /// Regimen copia sumptus effundit in Pemex, deversoriorum Sedenae et Conahcyt. /// Loret: Pío sustulit se pecuniam accepisse. /// Pugna pharmaci mercatoris, ea causa homicidiorum optimatium dominatorum. /// OCDE (O-Ce-De-E) Mexicum vectigalia augere suggerit. /// Hodie Sectio quinque Septentrionalis Tramenis Maianae exstruit inter anomalias. /// Interclusum: omisit pericula pecuniae ab T-MEC cum legem electricitatem rescindendo. /// 'Nullae quaestiones magnae sunt' in securitate: AMLO. /// ‘CONTENTIO politica’ ‘in Mexico’ ‘pro praeside’ ‘INCIPIT’. /// ‘Rerum narcoticorum MERCATORES’ ‘aeroplano non gubernato’ ‘tres milites’ ‘in Tepalcatepec’ ‘OCCIDUNT’. IN PARAGUAIA. ‘In Paraguaia’, ‘ratio opere carentium’ ‘DIMINUIT’. IN ARGENTINA. ‘SCANDALUM’ ‘in Societate Assecurationis Nationalis’ EST.

27-X-2023. IN ISRAEL. In die Martis. In ‘THE JERUSALEM POST’ ‘LEGITUR’: ‘COPIAE ad Israelem Defendendum (abbreviatione anglica ‘I-De-eF’)’ ‘INVASURI SUNT’. // ‘Yoav ‘GALANT, copiarum ad Israelem Defendendum Australis dux’, ‘DICIT’ ‘incursionem aere et terra et mare’ ‘FUTURUM ESSE’. // ‘HAMAS, factio politica Palestinensis’, ‘duos obsides’ ‘LIBERAT’. In die Mercurii. In ‘THE JERUSALEM POST’ ‘LEGITUR’: ‘Copiarum ad Israelem Defendendum (abbreviatione anglica ‘I-De-eF’) DUX’ ‘DICIT’ ‘nos ad terra invandendum’ ‘FUTUROS ESSE’. // ‘Hamas ROCHETA’ ‘in Israelis medio’ BATTUUNT’. // ‘MACRON’ ‘DICIT’ ‘coallitionem internationalem’ ‘contra Hamas’ ‘NECESSE ESSE’. // ‘OBSES liberatus’ DICIT’ ‘in inferno’ ‘FUISSE’. In die Iovis. In ‘THE JERUSALEM POST’ ‘LEGITUR’: ‘Beniaminus NETANJAHU, Bibi dictus et Israelis primus minister,’ ‘DICIT’ ‘duas res’: ‘de septem Octobris mense IUSTIFICATURUM ESSE’; et ‘dies ad terrae invadedum nondum NESCITURUM ESSE’. // ‘Biden’ ‘CONSIDERAT’ ‘primo expedire obsides’ ‘prudens EST’. // ‘COPIAE ad Israelem Defendendum (abbreviatione anglica ‘I-De-eF’)’ ‘DICIT’ ‘Iraniae interventum’ ‘patentem’ ‘ESSE’. // ‘Recep Tayyip ERDOGAN, Turciae praeses rei publicae,’ ‘DICIT’ ‘Hamas Motum pro liberatione ESSE’, ‘Motum terroristicum non ESSE’. In die Veneris. In ‘THE JERUSALEM POST’ ‘LEGITUR’: ‘IRANIA DIXIT’ quod ‘si pyrobolos contra Gazam CONTINUANT’, ‘Civitates Foederatae Americae’ PUNIETUR’. // ‘COPIAE ad Israelem Defendendum (abbreviatione anglica ‘I-De-eF’)’ ‘Gazam’ ‘in terra’ ‘APPUGNANT’ et ‘postea DETRAHUNTUR’. // In alia acta diurna LEGITUR: ‘CIVITATES Foederatae Americae’ ‘pyrobolos’ ‘contra Iraniae locos’ ‘in Syria’ ‘CONICIT’. IN CANADA. ‘CANÁDA’ ‘ad Civitates Foederatae Americae’ ‘armistitium in Gaza petendo’ ‘CONIUNGITUR’. // ‘Canádae ARGENTARIA’ ‘creditorum rationem’ ‘in quinque centesimis’ ‘RETINET’ IN CIVITATIBUS FOEDERATAE AMERICAE. ‘Wenevera ELLIS, Trump advocatus,’ quoque ‘conspirationis culpabilem’ ‘DECLARATUR’. // Denique, ‘FACTIO Republicana (abbreviatione anglica ‘Ge-O-Pe’)’ ‘camarae oratorem’ ‘ELIGIT’. ‘JOHNSON’ ‘sibi nomen EST’. // ‘Factionem Republicanam’ ‘JOHNSON’ CONIUNGENDA EST’. // ‘PERSECUTIO’ ‘contra trucidatorem, qui duodeviginti personas INTERFECIT’, ‘in Cenomannica’ ‘CONTINUAT’. // ‘Americae OECONOMIA’ ‘quattuor punctum novem centesimas’ ‘CRESCIT’. IN BRITANNIARUM REGNO. TRANSLATIONES ex Israele García Avilés SUNT: Sunak: canere ‘Jihad’ minatio est imperio populi. Princeps disciplinam publicam clamat et affirmat eam habere potentiam ut custodia retinet quos in odium incitat. // ISRAEL: Sunak Israelem urget: moram facere belli quod appronpinquat in Gazam. IN INDIA. TRANSLATIO ex Casandra Freire EST: Israel poscit Indiam denuntiare Hamas terror esse. // ‘Quatariae TRIBUNAL Iudicialis’ ‘poenam catpitalem’ ‘contra octo indicos’ ‘MANDAVIT’. IN SINIS. TRANSLATIONES ex Israele García Avilés SUNT: Li Shangfu spoliatus cursis publicis militaribus. Civitates Foederatae Americae poenam irrogat ei et expulerunt eum ex societate ‘Pe-eL-A’ etiam spoliatus fuit consiliis reipublicae, per meses absenti vitae publicae. // Bhutan et respublica popularis Sinarum multum in sermonis de finibus patribus proficiunt. IN EUROPA. TRANSLATIO ex Casandra Freire EST: Pacto Atlantico Septentrionali: Erdogan voluntati Suetia satisfacit. IN UCRAINA. ‘Octigenti pueros’ ‘a Kherson’ ‘DECEDUNT’. // ‘PUGNAE’ ‘in Kharkiv et Kherson et Avdivka’ ‘SUNT’. // Etiam ‘PUGNA’ ‘in SUMY’ ‘EST’. IN CIVITATE VATICANA. ‘SINODUS’ ‘documentum cui titulus ‘Epistulam ad Dei Populum’’ ‘viginti quinque Octobris mense’ ‘EVULGABIT’. // ‘FRANCISCUS’ ‘deprecationem pro pace’ ‘CONVOCAT’. IN QUATARIA. ‘Quatariae EMIR’ ‘cum Hamas et cum Occidens’ ‘in actibus’ ‘EST’. IN NICARAGUA. ‘ORDO Fratrum Minorum’ ‘sine iuris statu’ ‘in Nicaragua’ ‘SUNT’. IN HAITIA. ‘HAITIA’ ‘in proximum discrimen’ ‘EST’. IN SUDANIA. ‘Colloquia’ ‘pro pace’ ‘in Sudania’ ‘RESTAURANT’. IN NIGRE. ‘Unionis Europae SANCTIONES oeconomicas’ ‘contra Nigrim’ ‘SUNT’. IN ORBE TERRARUM ‘Silvarum VASTATIO’ ‘in orbe terrarum’ ‘CRESCIT’. // ‘ANTARCTICA’ ‘LIQUEFIT’. IN FRANCIA. ‘Emmanuel MACRON, praeses Rei Publicae Franciae’, ‘Israeli’ ‘ad scaenam politicam proponendum’ ‘VISITAT’. // ‘Emmanuel MACRON’ ‘in Israele’ ‘magnus funambulus politicus’ ‘FUIT’ quia ‘sermones’ ‘pro Israele et pro Palaestina’ ‘EDIXIT’. // ‘Rete terroristica quorum Islamicam religionem fanatice sequitur (anglice ‘jihadist’)’ ‘ad Iudicium’ ‘VADENT’. IN BELGIO. ‘Bruxellarum REGIMEN’ ‘tributorum augmenta et donationum abundatiora receptiones’ ‘APPROBAT’. // ‘Institutum Nummarium Orbis Terrarum (abbreviatione hispanica ‘eF-eM-I’)’ ‘pretiorum incrementum’ ‘plus quam quattuor centesimas’ ‘anno proximo’ ‘pro Belgio’ ‘PROSPICIT’. IN LIBANO. TRANSLATIO ex Casandra Freire EST: Libani in metu sunt ne novum bellum cum Israel esse. IN CIVITATIBUS FOEDERATIBUS AMERICAE. ‘Septem mortui’ ‘in magno casu sinistro centum quinquaginta octo autocinetorum’ ‘FUERUNT’. IN MARE SEPTENTRIONALI. ‘Collisio’ ‘inter naves onerarias’ ‘in Mare septentrionali’ ‘FUIT’. IN EUROPA. ‘Europae Centralis ARGENTARIA’ ‘creditorum rationem’ ‘hac data occasione’ ‘non AUGMENTAT’. IN GERMANIA. ‘Sara WAGENKNECHT, diurnaria et rerum politicarum perita Theodisca (EX VICIPAEDIA)’, ‘factionem politicam propriam’ ‘INSTITUIT’. // ‘Robertus HABECK, Germaniae administer foederalis oeconomiae,’ ‘subsidia’ ‘pro industriis’ ‘PROPONIT’. // ‘De celeribus deportationibus’, ‘FACTIO Viridis’ ‘contra Nancy FAESER, Germaniae Administra Foederalis Rerum Internarum’, ‘PUGNANT’. // ‘MANIFESTATIONES’ ‘anti-Israelem’ ‘in Germania’ ‘SUNT’. IN HISPANIA. ‘Factio Socialis Opificum Hispanicorum (abbreviatione hispanica ‘Pe-eS-O-E’) et ‘Factio Addere (in lingua hispanica ‘Sumar’)’ ‘CONVENIUNT’. IN MEXICO. ‘Tredecim vigiles’ ‘in Guerrero, Mexico’ ‘NECANT’. // ‘Mexici OECONOMIA’ ‘tres punctum quinque centesimas annuus in Augusti mense’ ‘CRESCIT’. // ‘CURIA Senatorum’ ‘Potestatis Iudicialis tredecim commissos’ ‘EXTINGUIT’. // ‘Pretiorum INFLATIO’ ‘cifra bassa’ ‘REMANET’. // ‘Turbo procellarum Otis nominatus’ ‘Acapulcum’ ‘DEVASTAT’. // ‘Turbo procellarum Otis nominatus’ ‘triginta personas’ ‘in Acapulco’ ‘OCCIDIT’. // Etiam, ‘tres personas errantes’ et ‘circa sexaginta tensionis electricae turres destructae’ et ‘circa quingentos milia domus sine electricitate’ ‘SUNT’. IN PANAMA. ‘Metallicorum conflictus magnus’ ‘in Panama’ ‘EST’. IN ARGENTINA. ‘Macri et Bullrich’ ‘pro Milei’ ‘in Argentinae comitiis’ ‘SUNT’. IN LUSITANIA. ‘TAXIRAEDARIUM, qui peregrinatores ingannabat,’ ‘APPREHENDUNT’. IN BRASILIA. ‘Paulopolis Universitatis RECTOR’ ‘calendarium scholarem’ ‘non MUTABIT’. IN PROMUNTORIO VIRIDI. ‘Pueri’ ‘in quinquaginta centesimis’ ‘delictorum sexualium’ ‘victimae’ ‘SUNT’. IN SANCTO THOMA ET PRINCIPI. ‘SANCTUS THOMAS ET PRINCEPS’ ‘coniurationem adversus rempublicam’ ‘in Gabonia’ ‘denuo ACCUSAT’. IN MOZAMBICO. ‘BA KA KHOSA’ ‘ad Praesidem’ DIXIT ‘non talem esse’. IN GRAECIA. ‘Subsidia’ ‘pro viatoribus’ ‘ERUNT’. // ‘MOODY’S’ ‘existimationem’ ‘contra Graeciae debitum’ ‘DEMITTIT’. IN IAPONIA. ‘De successione imperatoria’ ‘novum CONSILIUM’ ‘EST’. // ‘Nivium cancrorum marinum CAPTURA’ ‘hoc anno’ ‘AUGMENTABIT’. // ‘Iaponiae Primus MINISTER’ ‘pro familiae unitate’ ‘EST’. // ‘IENUM, Iaponiae numus’, ‘in gradu inferiore’ ‘huius anni’ ‘EST’.

Claire recently gave her first seminar at another university. She learned to think more broadly about who her audience is, and also realized that the main purpose of seminars might actually be the budding collaborations that form from interactions throughout the day, rather than the seminar itself. Ruth finds that presenting to an audience that she doesn't know can be liberating. Ruth is working on being less stressed about giving seminars to the public - she fears that questions from a general audience are more likely to be outside her expertise. Claire's “folkestral rock” band, The Oyster Baes, released their debut album, Pearls. Listen anywhere, including on bandcamp.Do you have any fun/educational/relatable seminar stories? Share them with us at contactprofessorpodcast@gmail.com. professorpodcast.simplecast.com

W spotkaniu wzięli udział: ➤ Jacek Kopciński polski historyk literatury, dramatolog i krytyk teatralny. Profesor Instytutu Badań Literackich PAN oraz Uniwersytetu Kardynała Stefana Wyszyńskiego w Warszawie. Redaktor naczelny miesięcznika „Teatr”. Dramatolog, krytyk literacki, autor książki Powrót „Dziadów” i inne szkice teatralne. ➤ Bernadetta Kuczera-Chachulska poetka, profesor nauk humanistycznych, związana jest z Uniwersytetem Kardynała Stefana Wyszyńskiego w Warszawie. Inicjatorka czasopisma „Colloquia Litteraria”, jest także inicjatorką serii „Zeszyty Zakładu Aksjologii i Estetyki Literackiej” oraz „Problemy Romantyzmu”. Organizatorka cyklu konferencji naukowych „Colloquia romantyczne”. ➤ Andrzej Waśko historyk literatury polskiej, profesor nauk humanistycznych, wydawca, publicysta, redaktor naczelny dwumiesięcznika „Arcana”. Autor książek, m.in.: Romantyczny sarmatyzm. Tradycja szlachecka w literaturze polskiej lat 1831-1863, Historia według poetów. Myślenie metahistoryczne w literaturze polskiej (1764-1848). Andrzej Ferenc aktor filmowy i teatralny, lektor, narrator, reżyser i wykładowca akademicki, grał w Teatrze Rozmaitości, Teatrze Dramatycznym i Teatrze Współczesnym w Warszawie, założyciel sceny w Domu Literatury w Warszawie. Poezję czyta Andrzej Ferenc Dofinansowano ze środków Ministra Kultury i Dziedzictwa Narodowego pochodzących z Funduszu Promocji Kultury – państwowego funduszu celowego.

Have you been told to move on, look at the positives, be happy when you're at a low phase in your life? What if experiencing that particular emotion is what will help you evolve as an individual? In part two of Varun's conversation with Prakhar, they delve a little deeper into a topic they both enjoy – psychology. They tackle topics like their learnings from literature, their experiences with new cultures, and the follies of self-diagnosing their emotional state on Google. Prakhar also talks about the power of music to invoke emotional memories. Prakhar is a social commentator and a cultural critic. He's been a popular public figure in the public speaking and personal development domain for over 5 years. He hosts the PG Radio podcast and Prakhar ke Pravachan YouTube Channel – both have seen tremendous success. He co-founded Colloquia, a prominent Debate and Discourse club at Columbia University. In less than a year, Prakhar rose to become one of India's most popular public speakers. He has given 8+ keynotes at some of India's top institutions, including IITs and a TEDx talk. Time Stamps (00:00 - 01:12) - Intro (01:12 - 13:05) - Psychology vs Self Help (13:06 - 14:42) - No FAP (14:43 - 16:40) - Ego (16:41 - 17:34) - The Experiment in Porcupine Tree - Voyager 34 (17:35 - 21:04) - Slow Growth (21:05 - 29:32) - Tackling Trauma (29:33 - 36:35) - The importance of meditation & isolation (36:36 - 38:05) - How Prakhar takes a pause (38:06 - 39:12) - Outro You can Order Varun's book “Everything is out of syllabus: An instruction manual for life & work “ at https://amzn.to/335QKow Follow Varun across social media platforms @VarunDuggi https://www.instagram.com/varunduggi/ https://www.youtube.com/c/VarunDuggi https://twitter.com/varunduggi And for a weekly download of mind musings and recommendations subscribe to his newsletter “Unschooled with Varun Duggirlala” at https://varunduggi.substack.com About the show “Take a pause with Varun Duggirala” ( previously “The Varun Duggi show”) is a thrice a week podcast that's meant to enable its listeners to take a pause amidst the chaos of their daily lives to learn tools, embrace ideas and soak in concepts that will help them find motivation, build the right mindset and perform at their best. Varun also occasionally taps into the minds of truly interesting people to give listeners a learn from and use in their work, life, and everything in-between. --- Send in a voice message: https://anchor.fm/take-a-pause-varun-duggi/message

Do you find yourself often swallowing your opinion? Do you not feel confident enough to share your thoughts with the world? Maybe the main obstacle blocking you from unlocking your self-confidence is you. In this captivating episode of Take aPause, Varun talks to Prakhar Gupta on a lot of different topics. This episode covered so many wonderful topics that it had to be a two-part series. Prakhar is a social commentator and a cultural critic. He's been a popular public figure in the public speaking and personal development domain for over 5 years. He hosts the PG Radio podcast and Prakhar ke Pravachan YouTube Channel – both have seen tremendous success. He co-founded Colloquia, a prominent Debate and Discourse club at Columbia University. In less than a year, Prakhar rose to become one of India's most popular public speakers. He has given 8+ keynotes at some of the top institutions, including IITs, and a TEDx talk. Time Stamps (00:00 - 01:57) - Intro (01:58 - 07:25) - Confidence (07:25 - 11:57) - Travel & Backpacking (11:58 - 18:09) - Experimental phase of life (18:10 - 23:36) - Breaking down complex topics (23:37 - 29:52) - Building relationships with friends from Prakhars book (29:53 - 35:25) - Being Nice (35:26 - 47:09) - Saying No (47:10 - 1:01:44) - Talking to parents (1:01:44 - 1:06:23) - Psychology Books discussed in the episode Never Split the Difference: Negotiating As If Your Life Depended On It - Chriss Voss & Tahl Raz Outliers - Malcolm Gladwell Verbal Behavior - B. F. Skinner You can Order Varun's book “Everything is out of syllabus: An instruction manual for life & work “ at https://amzn.to/335QKow Follow Varun across social media platforms @VarunDuggi https://www.instagram.com/varunduggi/ https://www.youtube.com/c/VarunDuggi https://twitter.com/varunduggi And for a weekly download of mind musings and recommendations subscribe to his newsletter “Unschooled with Varun Duggirlala” at https://varunduggi.substack.com About the show “Take a pause with Varun Duggirala” ( previously “The Varun Duggi show”) is a thrice a week podcast that's meant to enable its listeners to take a pause amidst the chaos of their daily lives to learn tools, embrace ideas and soak in concepts that will help them find motivation, build the right mindset and perform at their best. Varun also occasionally taps into the minds of truly interesting people to give listeners a learn from and use in their work, life and everything in-between. --- Send in a voice message: https://anchor.fm/take-a-pause-varun-duggi/message

Listen to my reading of "Colloquia personarum" XV, from the LLPSI (Lingua Latina per Se Illustrata) book series. Colloquium personarum XV Latine recitatum. This is part of "Lectiones aestivae", the summer series where I read passages of Latin texts from all ages. If you want more, here are some useful links:

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Pierwsze dni nowego miesiąca nastroiły nas refleksyjnie. 1 maja obchodziliśmy nie tylko Święto Pracy, ale także 17 rocznicę wstąpienia Polski do UE. Natomiast 3 maja świętujemy dzień Konstytucji. Każda z tych rocznic jest okazją do wyrażenia radości z uzyskanych praw, możliwości oraz wolności. Skąd więc ten tytułowy dylemat? Kilka tygodni temu ukazało się nowe tłumaczenie klasycznej antyutopii George'a Orwella „1984”. Coś, co miało być tylko koszmarnym snem, wizją pisarza, nadal jest niepokojące i nie traci na aktualności. Jaką drogę chcemy obrać? Czy otwartej na szukanie kompromisu dyskusji i w jej efekcie wyrobienia sobie zdania, czy zgody na działania jednej uprzywilejowanej grupy lub grup ograniczającej pozostałych współobywateli? Pełny tekst opisu zamieściliśmy na stronie internetowej naszego projektu: http://2historykow1mikrofon.pl/agora-czy-folwark/ WYMIENIONE W AUDYCJI PUBLIKACJE: Aby Warburg, Od Florencji do Nowego Meksyku, Gdańsk 2019. Tomasz Różycki, Próba ognia. Błędna kartografia Europy, Kraków 2020. Jahrbuch Polen 2021. Oberschlesien, Wiesbaden 2021. Jacek Kordel, Królestwo anarchii. W poszukiwaniu nowożytnych wyobrażeń Rzeczpospolitej i jej mieszkańcach, Warszawa 2020. Grzegorz Kucharczyk, Długi kulturkampf. Pruskie i niemieckie wojny kulturowe przeciw Polsce w latach 1795-1918, Warszawa 2020. Marxismus a medievistika: Společné osudy?, red. Martin Nodl, Piotr Węckowski, Praha 2020 (=Colloquia mediaevalia Pragensia, t. 22). Dziennik Gazeta Prawna, nr 83/2021 – Piotr Kofta, Jak być przyzwoitym, czyli lęki i nadzieje George'a Orwella, s. 34-36; Historia nie musi być filarem patriotyzmu. Z Łukaszem Niesiołowskim-Spano rozmawiają Klara Klinger i Grzegorz Osiecki, s. 82-85. #2historyków1mikrofon Krzysztof Ruchniewicz Blog: www.krzysztofruchniewicz.eu Facebook: Instagram: www.instagram.com/ruchpho/ Twitter: twitter.com/krzyruch YouTube: www.youtube.com/channel/UCT23Rwyk…iew_as=subscriber Przemysław Wiszewski Blog: www.przemysławwiszewski.pl Facebook: www.facebook.com/przemyslaw.wiszewski Instagram: www.instagram.com/przewisz/ Twitter: twitter.com/wiszewski YuoTube: www.youtube.com/channel/UCuq6q08E…iew_as=subscriber Do nagrania intro i outro wykorzystaliśmy utwór RogerThat'a pt. „Retro 70s Metal” (licencja nr JAM-WEB-2020-0010041).

This week feature a Double Feature of Discussions. In our first discussion, author Larry Allen and Associate Editor Justin Grodin discuss the article "An Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction: The EPIC-HF Trial." Then in our second discussion, author Benjamin Scirica and Associate Editor Sandeep Das discuss the Research Letter "Digital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control." TRANSCRIPT BELOW Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts, I'm Dr. Carolyn Lam associate editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, associate editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Dr. Greg, I really love these double features that we have in 2021. Let me tell you about the first one. We are going to be talking about the EPIC heart failure trial. That's the electronically delivered patient activation tool for intensification on medications in HFrEF. Very important results. Dr. Greg Hundley: Yes, Carolyn. And the second feature is going to evaluate an algorithm based cardiovascular risk management program to improve lipid and hypertension control. But before we get to the double feature, how about we grab a cup of coffee and start with some of the other articles in the issue? Dr. Carolyn Lam: My coffee is right here and I want to talk about, guess what? SGLT2 inhibitors again for this first paper. Dapagliflozin, as we know, reduces the risk of end stage renal disease in patients with chronic kidney disease. We saw that in the DAPA-CKD trial. However, the primary and secondary preventive effects of SGLT2 inhibitors on cardiovascular outcomes have not been studied in patients with chronic kidney disease, with and without diabetes. Dr. Greg Hundley: Well Carolyn, remind us a little bit, what were the end points in the DAPA-CKD trial? Dr. Carolyn Lam: Okay, well yes. DAPA-CKD as a reminder, randomized more than 4,000 participants with chronic kidney disease to dapagliflozin, 10 milligrams daily or placebo. The primary endpoint was a composite of sustained decline in GFR of more or equal to 50% or end stage kidney disease or kidney or cardiovascular death. The secondary end points were a kidney composite outcome, the composite of hospitalization for heart failure or cardiovascular death and all cause death. Now the current paper is a pre-specified subgroup analysis where authors led by Dr. John McMurray from University of Glasgow, divided patients into primary and secondary prevention subgroups according to the history of cardiovascular disease. And results showed that dapagliflozin reduced the risk of the primary composite outcome to a similar extent in the primary and secondary prevention groups. This was also true for the composite of heart failure hospitalization or cardiovascular death and all cause mortality. The combined cardio renal benefits of SGLT2 inhibitors in patients with chronic kidney disease with and without diabetes therefore are substantial, whether there is history of cardiovascular disease or not. Dr. Greg Hundley: Not very nice, Carolyn. Well, my paper comes from Dr. Pradeep Natarajan and his colleagues at the Massachusetts General Hospital. And Carolyn, this study evaluated whether premature menopause is associated with CHIP. For our listeners, CHIP stands for clonal hematopoiesis of indeterminate potential and it is the age related expansion of hematopoietic cells with leukemogenic mutations without detectable malignancy. And previously it's been shown associated with accelerated atherosclerosis. Dr. Carolyn Lam: Yikes. Greg, is pretty much our menopause associated with CHIP? Dr. Greg Hundley: Well Carolyn, the investigators, among 19,606 women, they identified 418 or 2.1% with natural premature menopause and 887 or four and a half percent with surgical premature menopause. Premature menopause, especially the natural premature menopause was independently associated with CHIP among post-menopausal women. Natural premature menopause, therefore may serve as a risk signal for predilection to develop CHIP and CHIP associated cardiovascular disease. Dr. Carolyn Lam: Interesting. Okay. Well, my next paper really provides the first evidence for endogenous induction of type-1 protein kinase A disulfide formation in the heart and this occurring after ischemia and re-profusion in both humans and mice. Dr. Greg Hundley: Ah Carolyn, so tell us more about this interesting paper. Dr. Carolyn Lam: Well, this is from Dr. Simon from University of Oxford and colleagues who used high spatial and temporal resolution imaging modalities in conjunction with an interesting redox dead type-1 protein kinase A knock-in mouse model and demonstrated that disulfide modification targets this type-1 protein kinase A to the lysosome where it acts as a gatekeeper for two poor channel mediated calcium release and prevents inappropriate triggering of calcium release from the sarcoplasmic reticulum. In the post ischemic heart, they found that inhibition of lysosomal calcium release by these oxidized molecules was crucial for limiting infarct size and preserving cardiac function during re-profusion. All this thus offering a novel target for the design of cardio-protective therapeutics. This is discussed in an editorial by Doctors Westenbrink, Nijholt, and deBoer from University Medical Center Groningen. Dr. Greg Hundley: Thanks, Carolyn. Very nice. Well, my last paper comes from Dr. Nicholas Marston and colleagues from the TIMI study group at Brigham and Women's Hospital of the Harvard Medical School. Carolyn, genome wide association studies have identified single nucleotide polymorphisms or SNIPs that are associated with an increased risk of stroke. The authors sought to determine whether a genetic risk score could identify subjects at higher risk for ischemic stroke after accounting for traditional clinical risk factors across five trials involving the spectrum of cardiometabolic disease. Dr. Carolyn Lam: Interesting. And these genetic risk scores are very hot. What did they find? Dr. Greg Hundley: Thanks, Carolyn. Among 51,288 subjects across the five trials, a total of 960 subjects had an ischemic stroke over a median follow-up of two and a half years. Across a broad spectrum of subjects with cardiometabolic disease, a 32 SNIP genetic risk score was a strong, independent predictor of ischemic stroke. In patients with atrial fibrillation, but lower CHA2DS2-VASc two scores, the genetic risk score identified patients with risk comparable to those with higher CHA2DS2-VASc two scores. Dr. Carolyn Lam: Wow, that really is impressive. Well, guess what? We've got some other articles in today's issue. There's a beautiful White Paper about the definitions and clinical trial design principles for coronary artery chronic total occlusion therapies and this from the CTOARC consensus recommendations by Dr. Rinfret and colleagues from McGill University. There's a Research Letter entitled, The Randomized Control Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients with Type II Diabetes. And this is from Dr. Hong and colleagues from Yonsei University College of Medicine in Korea. Dr. Greg Hundley: Thanks, Carolyn. Well I have an exchange of letters from Doctors Albiero and Xie regarding the previously published paper, Patent Foramen Ovale Could be a Source of Paradoxical Embolism and Lead to Adverse Outcomes in Hospitalized Patients with COVID-19 Pneumonia and DVTs.” There's also a Perspective piece to the 2020 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease from Dr. Bavry. And finally Carolyn, Dr. Tung has an ECG Challenge entitled, “Narrowing the Differential Diagnosis for a Wide Complex Tachycardia.” Well, how about we get on to both of our double features. Dr. Carolyn Lam: Let's go, Greg. Dr. Greg Hundley: Well listeners, we are here for our first feature discussion and we have with us today, Dr. Larry Allen from University of Colorado and our own associate editor, Dr. Justin Grodin from University of Texas Southwestern Medical School in Dallas, Texas. Welcome gentlemen. Larry, could you walk us through the background that really formulated your hypothesis? And then what was the hypothesis that you wanted to test with your study? Dr. Larry Allen: Well, thanks again for having me. I'm a heart failure doctor. The research group that I work with has spent a lot of time on patient empowerment and think about medication prescribing for HFrEF as shared decision making. Thinking about this as a discussion between the patient and me, rather than me deciding what to do. As you know, patients are now coming into the office because they've seen direct to consumer advertising around medications, but typically those are very biased. They're advertisements that are for only patented drugs. And what I'm really trying to think about is what is my patient's overall regimen in terms of heart failure? Dr. Larry Allen: And so we developed a tool which was a three minute video to tell patients that they should come into their visit and be excited to have discussions about their medicines and then a one page checklist that basically said, "Here's what an optimal regimen of medicines looks like for a patient with heart failure and reduced ejection fraction and nobody's really on a perfect regimen, but these are all the possibilities that you could have." Our hypothesis was that if we delivered that to patients before the clinic visit, that it would lead to better prescribing of these drugs. Essentially we imparted on a randomized trial within our healthcare system to do that and that's what we're discussing today, the results of the EPIC heart failure trial. Dr. Greg Hundley: Very nice, Larry. Tell us a little bit, what patients did you enroll in your trial? And then what outcomes did you work to assess? Dr. Larry Allen: We're part of the UC Health System, which has 12 hospitals, but a number of cardiology clinics across the front range of Colorado. Our entire system is on a single instance of the EPIC electronic health record so we're now able to essentially automatically identify all the patients in our system who have HFrEF. We generated lists of patients who had HFrEF who were going to see a cardiology provider in clinic and then we identified them ahead of time, enrolled them in the study prospectively. And the enrollment was for them to agree to be randomized in the study and then for us to be able to collect data on them. Dr. Larry Allen: The patients were kind of a wide range of HFrEF. They were an average of 65 years old, about 70% of the patients were male and reflected the race and ethnicity of Colorado with 11% Blacks and about 7% Hispanics. And everybody in the study had an ejection fraction of 40% or less on their last echocardiogram or other recent cardiac study. And then they were randomized to either get this three minute video sent to them as an email or as a text link that kicked them over to the one page checklist. And then we had them come in. A 145 patients came to clinic having got the information and a 145 patients just came to clinic like usual. Dr. Greg Hundley: Very nice. What did you find, Larry? What were your results? Dr. Larry Allen: Yeah, so we found not surprisingly that the majority of patients who were in usual care had no change to their medical regimen. What we found in the patients who received the EPIC heart failure three minute video and checklist, we saw about a 19% absolute increase in intensification of guideline directed medical therapy. And then we found that most of that was actually an increase in beta blocker dose prescribing. To some extent, the cheapest therapy that could be increased on a drug that people are already on. Dr. Greg Hundley: Very good. Well Justin, we'll turn to you. Help us put the results from Larry's work in the context of A, management of patients with heart failure and reduced ejection fraction and then also B, tell us a little bit about what attracted you to this article and maybe even where you see some of this going next. Dr. Justin Grodin: Thanks, Greg. And Larry, obviously I want to echo Greg's comments by thanking you for your submission. This was a paper that we thought obviously very highly of. Greg, for your first point, we've got novel therapies, but really one of the major issues now is not can we find a newer, better drug? I think we've all come to this realization, it's scalability and implementing these therapies into our regular practice, like beta blockers, RAS inhibitors and mineralocorticoid receptor antagonists. And as Larry said, the problem now is not the quality of our therapies, it's really scaling it and getting it to everyone. It's also increasing these therapies to optimum dosages in patients that can tolerate it over time. Dr. Justin Grodin: And then, to answer your second question, I think some of the things that struck us by this was that this is a wonderfully simple intervention that truly does empower patients. The majority of our interventions to optimize medical therapy has been targeting the physicians, the APP, the nurses, et cetera. This is beautiful in that it empowers the patient and we are putting the ball in their court. And I think to kind of dovetail with your third question, this is a health system clinical trial and I think that tells us a few things. I think one, it provides the framework on how one could perhaps implement that in their health systems. And we'll have to see if this is something that could translate to other health systems across the country or multiple centers. But I think really the intrigue with this work is that it all comes back to empowering the patients. Dr. Greg Hundley: Very nice. Dr. Larry Allen: Greg, I wanted to just add one thing that in the heart failure community, there's this argument going back and forth about whether the lack of optimization of guideline directed medical therapies is due to intolerance or whether it's due to therapeutic inertia. And one of the things I like about this study is on face value, we're empowering patients, but the fact that by asking patients to get involved in prescribing decisions, I think one of the take home messages is that this is partially about therapeutic inertia and that as clinicians, we have a lot of things we're dealing with. And if patients come in to the clinic visit and they're motivated to make these changes actually, we can intensify the therapy. Dr. Greg Hundley: Very good. Larry and Justin, both one at a time here quickly, in the last minute that we have, what do you see as the next study, Larry, that needs to be performed in this space? Dr. Larry Allen: I see two things quickly. One is, as Justin mentioned, validating that this kind of intervention, while simple can be pragmatically deployed in other health systems and in other contexts. The second thing is how do we integrate this kind of small intervention with the larger overall care of patients? One of the concepts that I've talked a lot about over the years with others, including Len Stevenson, is this concept of an annual heart failure review, where rather than seeing people on multiple short visits where we tackle small issues, we actually create a little bit of time to stand back and take a global view of heart failure therapy and how that heart failure therapy fits into the goals of care for the patient, the other medical problems they have and where they're headed. Dr. Greg Hundley: Very good. Justin, anything? Dr. Justin Grodin: Greg, I have to agree with Larry. I think he hit the nail on the head with his first comment. At least for me from an editorial standpoint is really we like to see how generalizable this is and really this implemented in other health systems. I think that's the logical next step. I can tell you, at least from our discussions at our medical center about this manuscript since it's been published at Circulation is, is there something like this we could implement in our own health system? Or in the health systems that we're affiliated with? Dr. Larry Allen: And I would just add that this research and the intervention was funded by the American Heart Association under the strategically focused research network for heart failure and so we've made the interventions public they're online at the research website we have, patientdecisionaid.org. Dr. Greg Hundley: Well fantastic. Well listeners, we want to thank Dr. Larry Allen from University of Colorado and our associate editor, Dr. Justin Grodin from UT Southwestern, for bringing us this article, demonstrating a process that facilitates patient physician interactions to improve the administration of guideline based therapy to patients with heart failure and reduced ejection fraction. And so we're going to wind up this feature discussion and we will head to our next feature. Dr. Greg Hundley: And we have with us Dr. Benjamin Scirica from Brigham and Women's Hospital and our own associate editor, Dr. Sandeep Das from UT Southwestern. Benjamin, could you tell us a little bit about the background information that you used to formulate your hypothesis that you wanted to test for this study? Dr. Benjamin Scirica: Thanks so much first for the invitation. It's a great honor to obviously be in Circulation and to be part of this podcast. We started with the recognition that in our practice, which is similar, I think to a lot of the United States, we are not doing as good a job as we could in terms of care for a lot of the chronic cardiovascular conditions we see. And hypertension and high cholesterol are one of those clear areas where we know there are very good guidelines with clear indication for therapy in specific situations and that these drugs that are available are predominantly generic. But when we looked at our registries, we found that we were not doing as well as we thought. We felt that there are a lot of reasons for that. Dr. Benjamin Scirica: A lot of it was based on the fact that for something good to happen, the right thing to happen, you have to have a patient and a doctor in the same room, the doctor has to recognize that there's a problem. They have to know that there is something they can do about it. They have to be able to convince the patient or educate the patient that they should start this new therapy. They have to know how to start the therapy and then have the ability to follow up and make sure that there is longitudinal care for these chronic diseases. Dr. Benjamin Scirica: And that's a lot to ask for any of us when we have 15 minutes to see the patient, we may only see the patient a couple times a year at most. And so we felt that our hypothesis is, could we design a program, would be delivered remotely, that would not require a doctor in the middle of all of these decisions and that we could scale by using lower cost resources, non-licensed healthcare coordinators or navigators and pharmacists who could follow very clear treatment algorithms to be able to identify patients and prescribe the right medicines to patients at the right time, based on their cardiovascular risk. Dr. Greg Hundley: What was your study design? And what was your study population? Dr. Benjamin Scirica: This is an active, ongoing quality improvement program where our hypothesis is that by doing this, we could improve patients' lipids and cholesterol prescriptions compared to prior. And we did some analysis and we saw that a lot of these patients had not been on optimal therapy for many years, even though they've been in our system. With the limitations of not having randomization, we identified these patients and through different clinics in the different hospitals, and would either have patients referred to us by providers or more commonly go and find them within the registries and identify the patients and contact them and have them enter our program where they would usually take somewhere between eight to 12 weeks to be actively managed, to get to their goals and then they'd enter a maintenance program. The report that we do now is that the story of the first 5,000 patients who we enrolled in our program of whom about 35% were still in management at the time we presented these ongoing results. Dr. Greg Hundley: Roughly how old were these participants? And what was the breakdown in terms of gender or sex distribution? Dr. Benjamin Scirica: We found that about 12% were over 75 years old, a little over half were female. We had 71% who are non-Hispanic Caucasian and 8% who were non-English speaking. In terms of their cardiovascular risks, about a third of the patients had established cardiovascular disease, about a quarter of the patients had diabetes and about a third had an LDL of more than 190 milligrams per deciliter, but no history of ASCVD or diabetes. And then for hypertension, we really would take anybody whom the physician felt required further blood pressure management, because their blood pressure was over 130 over 85. Dr. Greg Hundley: And what did you find? Dr. Benjamin Scirica: We found that of the 5,000 patients that we enrolled, about 4,000 were in the lipid program, a little over 1,400 we're in the hypertension program, so some patients were in both programs and in the lipid patients, in those patients who achieved maintenance, we increased lipid therapy, any lipid lowering therapy, from about 78% up to 97%. And that was predominantly through statins but we doubled the use of ezetimibe from 9% to 17%. We saw a small increase in PCSK9 inhibitor use from 1% to 3%. And if we looked at LDL reductions, it was a 52 milligram per deciliter reduction in LDL from an average LDL of a 125 down to 73 in those folks who achieved maintenance. For blood pressure, again, in those patients whom we successfully treated who are about 600 patients, we saw a 14 millimeter systolic blood pressure reduction and a seven millimeter mercury diastolic blood pressure reduction. Dr. Greg Hundley: Wow. Well Sandeep, what drew your attention to this? And then also, how do you put the context of these results with others that really are working in this wing of data science in cardiovascular medicine? Dr. Sandeep Das: Great question. We have a large body of literature that suggests that the use of these fantastic evidence based therapies like statins, like blood pressure medications is poor and we really struggle to improve those numbers. I wanted to applaud Ben and his group for really taking on, in a robust way, an important topic and subject. The other thing that really attracted me to this study, there was a hypertension expert here named Ron Victor back when I first started as a fellow. Fantastic researcher and he did a project called Colloquia called the Barbershop Project about leveraging pharmacists and barbers to improve the blood pressure control of African American men in the community. Dr. Sandeep Das: The idea is that you get out there, you got to go to where the patients are rather than expecting them to come to you. And you got to figure out ways to engage them, activate them, get them to participate in their own care. A fantastic study, but the one thing that always, we discuss that study, the thing that always jumps out is, well how do you scale it? How do you use it in a real practice? To me was also a very exciting aspect to this. The goal is to take steps to generalize from clinical trials to real world practice, because we got to get this to patients. Dr. Greg Hundley: Very nice. Well Ben, coming back to you, what do you see as next steps for your research here? And then even in the field? Dr. Benjamin Scirica: The first is, are there other disease areas we can do this in? I think the second part is how to test different techniques to try to improve the ability to scale it to broader populations and keep the cost down. And I think it is a combination of trying to find the right tools, whether they're digital or not and the right techniques to be able to activate patients, educate them, such that they are asking the question, "How come I'm not on these medicines? How come I'm not on this?" And I think we could do a lot in terms of AB testing in there. The part that I think is challenging in these healthcare studies and quality improvement studies, is that randomization would be great. How can we do it streamline? Do we need to get consent? Can it just be that approved drug A can be tested against approved drug B because there is clear equipoise. And I think by doing that, we could lower the bar for really pragmatic randomization in practice and be able to have much more rapid cycles of improvement and optimization on therapy. Dr. Greg Hundley: Very good. Sandeep, do you have anything to add? Dr. Sandeep Das: I'll echo Dr. Scirica's called arms here that we need to have a way to do this, do trials in this space pragmatically. I agree with that strongly. I did have a few thoughts on next directions. I work in a population of the urban poor of Dallas County with a lot of my clinical time and these patients have poor health literacy so I think that one question, not question but suggestion or comment to Ben and his group would be to think hard about how you would expand this to lower resource setting or to people that would be a little harder to reach. And even as sort of an aspirational goal, how do you expand it into the community? The other question that I would have is how much of this can we get by with adherence interventions? It's one thing to prescribe, but it's another thing to figure out how to get people to adhere to meds. Dr. Greg Hundley: Very nice. Well listeners, we want to thank Dr. Ben Scirica for Brigham and Women's and Dr. Sandeep Das from UT Southwestern, bringing us this really interesting research that has been providing early results of a remotely delivered pharmacist led lipid and hypertension management strategy that dramatically increased medication compliance and improved hypertension control and lipid management. Dr. Greg Hundley: On behalf of Carolyn and myself, we want to wish you a great week and we will catch you next week on the run. Dr. Greg Hundley: This program is copyright of the American Heart Association, 2021.  

00:00 Begin.7:08 The 'Steel Man'8:30 Steel manning dangerous individuals. 9:40 Suspend your own position. 10:58 Separating the idea from the individual. 12:26 Steel manning the opposite. 14:10 The University and acquiescing to student demands. 17:01 Beginning of our Journey.18:37 Jonathan's GS Story.19:15 Prakhar's GS Story. 27:00 Perry's GS Story. 32:24: Challenging God. 38:51 Conversations on a street couch.  41:38 Philosophy of Humor. 45:08 Colloquia inception. 45:50 Are ideas dangerous?48:10 Power dynamics in conversation. 58:26 Plato's theory of play. 59:29 Red/Blue Team1:03:45 Playing with ideas. 1:07:48 Favorite Stoas. 1:12:30 Professor Abe Haak Event1:16:37 Jonathan's Hot Seat1:20:55 Steel Man: Hiroshima bombing. Topic in a Hat. 1:23:23 Stoa: Colloquia Critique 1:27:19 Stoa: Monitoring Chinese Students1:34:43 Hopes for the future. 1:37:51 Humility and Death. 1:42:55 The utility of Philosophy. 1:46:37 The University as a bubble. 1:56:43 What Colloquia did for Prakhar. 2:02:48 The Stoa as an experiment. 2:03:44 End 

Prakhar is joined by Patricia Marcoccia and Maziar Ghaderi, the co-creators of the docu-film The Rise of Jordan Peterson, and Parvir 'Perry' Sidhu, the founder president of Colloquia. Patricia and Maziar are the cofounders of Holding Space Films in Canada and are currently touring with the film screening it across the world. Prakhar, Perry, Maz and Patricia talk about Peterson's influence on their work, the culture wars of our times, the film making process, the interaction of art and activism and objectivity in the domain of artistic activism. Holding Space Films Twitter- /holdspacefilms Instagram- @holdingspacefilms Facebook- /Holdingspacefilms Email- lestalk@holdingspacefilms.com Website for the film- riseofjordanpetersonfilm.com Colloquia Instagram- @cucolloquia Facebook- /cucolloquia/ Perry's instagram- @iparvir

Perry Sidhu grew up in the small town of Redding in Northern California before he moved to LA to become an actor. He is now a student of Philosophy at Columbia University. Perry is the co-founder and founding President of Colloquia - a multi-partisan organization that pursues the a free exchange of ideas as a fundamental value to its academic setting. On this episode of the podcast we discuss Colloquia and the questions and controversies that come with it. Perry delves into the journey of Colloquia's inception, the trysts he and his team faced pre and post it's inceptions and the many components of Colloquia's culture. TO SUPPORT THIS PODCAST SUBSCRIBE TO IT AND LEAVE A REVIEW. I ALWAYS READ THEM IN THE HOPE TO MAKE THIS A BETTER EXPERIENCE FOR ALL OF YOU.

in quō discimus quam doctē Google Trānslāte nōs adiuvet Schola Latina Corcagiensis

Managing Director of Research at Filene, Andrew Downin, speaks with me about the Institute's research strategy pivot to the 5 Centers of Excellence as well as our 5 Colloquia (NOT Colloquiums!) happening throughout this year. I've also included a mini-interview with Filene Fellow Huggy Rao who offers deeper explanation of his 7 mantras for scaling excellence. Pro tip: Email Andrew at AndrewD@Filene.org to get more info on participating in research or other activities with Filene AND to find out when the snow pile outside his office window finally melted (or has it not yet?? You won't know till you ask Andrew!) Check out resources mentioned in our discussions: Scaling Up Excellence research report: https://filene.org/research/report/scaling-up-excellence Research Colloquia: https://filene.org/join/calendar/category/research-colloquium Centers of Excellence: https://filene.org/research/centers-of-excellence

Today’s podcast offers PART 2 of interviews recorded at CUNA's Governmental Affairs Conference at the end of February. With Visa SVP, Doug Leighton, head of community accounts, we talk about Filene's 5th Center of Excellence, focused on the war for talent. Doug shares why Visa finds it so important to support credit unions, to help them win top talent in the face of intense competition and help bring an entire generation, first as employees and then as members, into the credit union movement. Check out PART 1 of this podcast first if you haven't yet: https://soundcloud.com/user-306424525/filene-fill-in-ep-25-shoe-twins-sekou-and-george-on-attracting-top-talent Then take a trip over to Filene.org to check out each Center of Excellence and the Colloquia: https://filene.org/research/centers-of-excellence

Decades before the Civil War, the actions of a brutal overseer spark the fire of revolution on a Southern Tobacco farm. Tobacco Burn chronicles true events and creates a portrait of man's different understanding towards violence. Justin Liberman-Communication and Media Studies Anita August- Rhetoric and Writing Studies

Our society has identified the damage bullying can have on the emotional and physical life of the victim. The next step is to discover the personal resilience to confront bullying. Recognize your positive power to address bullying behavior directed towards you or others. This extraordinary colloquium will integrate Dr. Terry Neu talking about how to prevent bullying with the SHU 4 Heart Harmony led by Dr. Michniewicz performing their anti-bullying concert.

Will look at recent artwork made in prison—a range of production from mainstream prison art, with its reliance on tattoo imagery, to prison folk arts like soap carving and toilet paper sculpture, to powerful drawings and paintings by outstanding individual artists, with quotes from men and women in institutions from county jail to death row. They are candid and insightful about their lives, their art, and their imprisonment. Phyllis Kornfeld, author of Cellblock Visions: Prison Art in America, (Princeton University Press), has been conducting visual art programs with incarcerated men and women for thirty years.

Students will engage in a multi-disciplinary discussion of crimes against others because of race, religion, ethnic or national identity, sexual orientation. What are hate crimes? Why are there hate crimes? What can be done about hate crimes? Professors June-Ann Greeley (Theology/Religious Studies), Jennifer McLaughlin (History), and Amanda Moras (Sociology)

In this third Colloquium of our series, we will discuss the most vexing questions that face us in the aftermath of this tragedy. Such tragic events as the Sandy Hook massacre bring many of us to ask why does such irrational evil occur and in the face of this evil, where is God? There are no firm answers to such questions but these questions call for our reflection and discussion. Dr. June-Ann Greeley will facilitate discussion with local interfaith clergy

An overview will be given of what PTSD is and how it affects a person. We will hear from two veterans and their unique situations in the Marine Corps and how they are overcoming PTSD.

Learn 10 strategies on how your emotions can be used to create happiness and provide you with a more fulfilling life of meaning and purpose.

Colloquia: Zombies, Souls and Fear of the Flesh, Spring 2013

Gail Fosler

Plastic Planet, Spring 2013

Hate Crimes: Power, Prejudice and Personhood Presented by: JUNE-ANN GREELEY, THEOLOGY and RELIGIOUS STUDIES Alka Jauhari. Government and Politics JENNIFER McLAUGHLIN, HISTORY AMANDA MORAS, SOCIOLOGY Wednesday, December 5th ~ University Commons

Colloquia: The Honors Freshman Year Experience Monday ~ December 3, 2012

Colloquia: The Truth About Suicide Pitt Center Board Room November 29, 2012

Colloquia: Human Rights Violations

Veterans on Trial deals with the problem of PTSD from the ground up, starting with the issues that returning veterans and their families face. When they leave the battlefield to become civilians again, many soldiers are not prepared, or are unable, to cope successfully with the challenges. Their compounded anxieties often result in serious trouble; divorce, job loss, homelessness, substance abuse, suicide, and even murder. Judge Schaller will explain how PTSD now operates as a means of defense in the criminal court system and how it will affect the courts in the next decade. Guest speaker Judge Barry Schaller (teaches courses on law, literature, and jurisprudence to state court judges. Teaches on the adjunct clinical faculty of the Yale Law School and is an Associate Fellow at Branford College, Yale University. Visiting Lecturer at Wesleyan University and Trinity College and a Visiting Lecturer at Yale University and a Guggenheim Fellow at the Yale Law School and an Adjunct Professor at Quinnipiac Law School)

Dr. Bettina Bildhauer, Reader an der St Andrews University in Grossbritannien, unterhält sich mit Dr. Udo Thiedeke über die Nähe des Mittelalters zu unserem Denken, die Grenze zwischen Subjekten und Objekten und warum wir beim Blick zurück entdecken können, wie die Dinge das Handeln lernten. Shownotes: #00:03:30# Kritik der modernen Vorstellungen von der angeblichen Weltsicht einer "flachen Erde" im Mittelalter. Vgl. z.B. Jeffrey Burton Russell, 1991: Inventing the Flat Earth. Columbus and Modern Historians. New York: Praeger. Jürgen Wolf, 2004: Die Moderne erfindet sich ihr Mittelalter – oder wie aus der ‚mittelalterlichen Erdkugel‘ eine ‚neuzeitliche Erdscheibe‘ wurde (= Colloquia academica Nr. 5), Stuttgart: Steiner. #00:04:10# Zu den Vorstellungen des Soziologen Max Weber zum okzidentalen Sonderweg des Rationalismus. Vgl. z.B. Wolfgang Schluchter, 1980: Rationalismus der Weltbeherrschung. Studien zu Max Weber. Frankfurt/M.: Suhrkamp. Besonders S. 23-38. #00:07:10# Keine universelle Gültigkeit des christlichen Weltbilds im Mittelalter. Vgl. z. B. Robert Bartlett, 2008: The Natural and the Supernatural in the Middle Ages. Cambridge: Cambridge University Press. #00:08:57# Zur Trennung von Subjekt und Objekt in der Moderne kann man vielleicht festhalten, dass die mittelalterliche Vorstellung, das Subjektive sei das Sein der Dinge und die Objekte realisierten sich in den Gedanken davon (etwa bei Wilhelm von Ockham) in der Moderne dahingehend überschritten wird, dass das Subjekt als nur noch sich selbst unterworfenes Objekte nur wahrnimmt (Kant) oder sich den Objekten in seiner Umwelt nun gegenüber sieht und diese manipuliert (etwa bei Marx und Engels). #00:11:50# Mittelalterliche Vorstellungen von Menschen als Teil von Netzwerken. Vgl. z. B. Jan-Dirk Müller, 1998: Spielregeln für den Untergang. Die Welt des Nibelungenliedes. Tübingen: Niemeyer oder Jeffrey Jerome Cohen (Hrsg.), Animal, Vegetable, Mineral. Ethics and Objects. Washington, DC: Oliphaunt, Online. #00:13:10# Zur Bedeutung des Blutes im Mittelalter siehe Bettina Bildhauer 2006: Medieval Blood. Cardiff: University of Wales Press; oder Caroline Walker Bynum, 2006: Wonderful Blood. Theology and Practice in Late Medieval Germany and Beyond. Philadelphia, PA: University of Pennsylvania Press. #00:15:48# Die Ebstorfer Weltkarte. #00:16:25# Die Gog und Magog. #00:17:00# Zum Frontispiz und Ikonografie des Leviathan vgl. Horst Bredekamp, 2003: Thomas Hobbes, Der Leviathan. Das Urbild des modernen Staates und seine Gegenbilder. 1651 - 2001. Berlin: Akademie Verlag. #00:18:55# Zum Staat als Körper im Policraticus des John of Salisbury vgl. z.B. Jacques Le Goff, 1989. Head or Heart? The Political Use of Body Metaphors in the Middle Ages. In: Michel Feher, Ramona Naddaff und Nadia Tazi (Hrsg.) Fragments for a History of the Human Body, Part 3. New York: Zone Books, S. 12-26. #00:19:12# Herbert Spencer, Gesellschaft als Organismus. Vgl. Spencer, Herbert, 1967: The Evolution of Society. Selections from Herbert Spencer's Principles of Society. Hrsg. Robert L. Carneio. Chicago: University of Chicago Press. #00:21:10# Die Siegfried-Sage als Teil der Nibelungensage und das Nibelungenlied. #00:27:18# Zur französischen Annales-Schule in der Geschichtswissenschaft. #00:31:00# Zahlreiche Ratgeber zur Selbstverbesserung des perfekten höfischen Menschen (Fürstenspiegel), z. B. Thomasin von Zirklaere, Der wälsche Gast #00:34:00# Positives Verständnis der Selbstaufgabe im Mittelalter, besonders in der Mystik, vgl. Kurt Ruh, Geschichte der abendländischen Mystik. 4 Bände. München: Beck, 1990-1999. #00:36:40# Zum Mittelalter als mythischer Vorgeschichte vgl. Arthur Lindley, 1998: The ahistoricism of medieval film. Online. #00:40:00# Zum Ritter als Assemblage vgl. Jeffrey Jerome Cohen, 2003. Medieval Identity Machines. Minneapolis, MN: University of Minnesota Press. Besonders Kapitel 2 Chevalerie. #00:41:05# Zu den Effigies vgl. Horst Bredekamp, 2001: Vom Wachskörper zur Goldkrone. Die Versprechungen der Effigies. In: Deutsches Historisches Museum et al. (Hrsg.): Preußen 1701. Eine europäische Geschichte. Aust.-Kat. Essay-Bd. Berlin. S. 353-357. #00:43:39# Zu Bruno Latours Kritik der Moderne vgl. Bruno Latour, 1995: Wir sind nie modern gewesen. Versuch einer symmetrischen Anthropologie. Berlin: Akademie Verlag. #00:44:13# Die Turnschuhe, in denen Joschka Fischer den Amtseid als hessischer Umweltminister ablegte, heute im "Haus der Geschichte" in Bonn ausgestellt. #00:44:52# Zur Struktur des Rhizoms von Deleuze und Guattari vgl. Gilles Deleuze und Félix Guattari, 1977: Rhizom. Berlin: Merve. #00:46:50# Subjekt-Objekt-Unterscheidung im Mittelalter weniger ausgeprägt. Vgl. Kellie Robertson, 2008. Medieval Things: Materiality, Historicism and the Premodern Object. Literature Compass 5. Online. #00:48:00# Bücher über die Kraft der Edelsteine z. B. von Albertus Magnus, hier Abdruck eines englischen Druckversion von 1604. Online. #00:50:40# Podcast Episode mit Markus Hilgert "5412 Jahre Vertrauen in Materialität - Prof. Dr. Markus Hilgert im Gespräch" #00:51:37# Zu den anfänglichen Problemen mit der Glaubwürdigkeit von handschriftlichen Texten beim Übergang von der Oralität zur Literalität verweist Walter Ong auf Clanchy, 1979: 24f. Vgl. Michael T. Clanchy, 1979: From Memory to Written Record, England 1066-1307. Cambridge: Harvard University Press. #00:55:40# Zur Behauptung einer Umbruchphase in der Literatur im 13. Jhr. vgl. Christa Bertelsmeier-Kierst und Christopher Young (Hrsg.), 2003: Eine Epoche im Umbruch. Volkssprachliche Literalität 1200-1300. Cambridger Symposium 2001. Tübingen: De Gruyter. #00:56:10# Zur Veränderlichkeit von mittelalterlichen Texten in Manuskripten (statt Erhalten eines "Originals") siehe Forschungen der "New Philology". Vgl. Paul Zumthor,1972: Essai de poétique médiévale. Paris: Seuil. #00:57:20# Informationen zum Codex Manesse in der Universitätsbibliothek Heidelberg. #00:59:40# Zur Macht der Gegenstände im Mittelalter im Sprachgebrauch, siehe Bettina Bildhauer, 2013: Der Gralsroman aus Sicht des Grals: Stil und das Mithandeln der Dinge. In Elizabeth Andersen, Ricarda Bauschke, McLelland (Hrsg.): Stil: Mittelalterliche Literatur zwischen Konvention und Innovation. Berlin: Akademie Verlag oder James A. Schultz, 2006: Courtly Love, the Love of Courtliness, and the History of Sexuality. Chicago: University of Chicago Press. #01:00:05# Zum mittleren Modus und Zigarettenrauchen siehe Bruno Latour, 2010: On the Cult of the Factish Gods, trans. Catherine Porter und Heather MacLean, in: ders.: On the Modern Cult of the Factish Gods. Durham, NC: Duke University Press. S. 1-66. #01:04:50# Zur KI (Künstlichen Intelligenz) oder AI (Artifical Intelligence) Online. #01:05:27# Zu Flussers Überlegungen über ein "neues Mittelalter" vgl. Vilém Flusser, 1993: Die Wiederkunft des Mittelalters. In: ders. Nachgeschichte. Eine korrigierte Geschichtsschreibung. Schriften Bd. 2. Bensheim/Düsseldorf: Bollmann. S. 143-154. Zu Filmen und neuen Medien als Boten eines neuen Mittelalters siehe Bettina Bildhauer, 2009: Vorwand into the passt. Film as a medieval medium. In: Anke Bernau, Bettina Bildhauer (Hrsg.), Medieval Film. Manchester: University of Manchester Press. S. 40-59. #01:06:17# Zum wachsenden wissenschaftlichen Interesse an Materialität siehe etwa: Jan-Hendrik Passoth, 2008: Zum Verstehen von Dingen: die sprachliche Erforschung des Nichtsprachlichen in verschiedenen Disziplinen, in: Karl-Siegbert Rehberg, Dana Giesecke, Thomas Dumke (Hrsg.): Die Natur der Gesellschaft. Verhandlungen des 33. Kongresses der Deutschen Gesellschaft für Soziologie in Kassel 2006. Teilbd. 1 u. 2. Frankfurt/M., New York: Campus. S. 1990-1999. #01:09:10# Ray Kurzweil entwickelt Ideen zur Speicherung des Gedächnisses. Online. #01:10:10# Zur mittelalterlichen "Gehirn-Bibliothek" Mary Carruthers, 2008: The Book of Memory. A Study of Memory in Medieval Culture. Cambridge: Cambridge University Press. #01:11:10# Zur Erfahrung der Macht der Dinge in der Weimarer Republik und im Weimarer Kino vgl. Thomas Elsaesser, 2000: Weimar Cinema and After. Germany’s Historical Imaginary. London: Routledge; Hermann Kappelhoff, 2000: Jenseits der Wahrnehmung - Das Denken der Bilder: Ein Topos der Weimarer Avantgarde und ein ‘psychoanalytischer Film’ von G. W. Papst. In: Harro Segeberg (Hrsg.): Die Perfektionierung des Scheins. Das Kino der Weimarer Republik im Kontext der Künste. Mediengeschichte des Films 3. München: Fink, S. 299-318 oder Béla Balázs, 2001: Der sichtbare Mensch oder die Kultur des Films. Frankfurt/M.: Suhrkamp. #01:14:10# Zur sog. Schwarmintelligenz vgl. z.B. Constanze Kurz und Udo Thiedeke, 2010: Picknick mit Cyborgs. Ein interdisziplinäres Gespräch über die alltägliche Vernetzung. München: Grin S. 97/99; Ingeborg Breuer, 2012: Schwarmintelligenz im Internet. Modebegriff für neue demokratische Formen. Deutschlandfunk. Studiozeit. Aus Kultur und Sozialwissenschaften. 28.06.2012 Online. #01:17:00# Zu Vilém Flussers Vorstellung vom Übergang von Daten (dem Gegebenen) zu Fakten (dem Gemachten) vgl. Vilém Flusser, 1998: Technik entwerfen. In: Ders.: Vom Subjekt zum Projekt Menschwerdung. Frankfurt/M.: Fischer TB-Verlag. S. 133-146. [alle Links aktuell Oktober/November 2012] Dauer 01:20:10 Folge direkt herunterladen

Colloquia: Body Image Fall 2012 Presented by: Dr. Jennifer Gosselin Psychology Jocelyn Novella Counseling Center

Guest Speaker- Dr. Michael Dobkowski

Learn 10 strategies on how your emotions can be used to create happiness and provide you with a more fulfilling life of meaning and purpose.

Since the brutal Civil War in El Salvador, Sacred Heart University faculty, staff and students have travelled to stand in solidarity with the Salvadoran people. This year will mark the 21st journey to El Salvador where a delegation and their advisors will listen to the stories and aide in the struggles of the people. This colloquia will include a history of the Sacred Heart and El Salvador relationship through the eyes of past delegates and advisors. They will share stories and experiences while encouraging others to share in this very important mission.

Colloquia: Gender and Media (Fall 2012)